sequence,pam,gc,efficacy_proxy,safety_score,assassin_score,provenance,mission_step,target_gene,target_variant,clinvar_classification,evidence_tier,plddt_mean,iptm,structural_confidence,structural_verdict
ATCCAGACAACTGTTCAAAC,NGG,0.4,0.65,1.0,0.6285050000000001,"{'design_method': 'evo2_prompt_guided_v1', 'safety_method': 'heuristic_v1', 'safety_status': 'ok'}",primary_growth,BRAF,p.Val600Glu,Pathogenic,"Tier 1 - FDA approved drugs (vemurafenib, dabrafenib)",67.36,0.37,0.522,PASS
CAAAATCACCTATTTTTACT,NGG,0.25,0.4,0.432,0.358105,"{'design_method': 'evo2_prompt_guided_v1', 'safety_method': 'heuristic_v1', 'safety_status': 'ok'}",primary_growth,BRAF,p.Val600Glu,Pathogenic,"Tier 1 - FDA approved drugs (vemurafenib, dabrafenib)",,,,
ATATTTGTCCCATTTACTGA,NGG,0.3,0.55,0.6,0.46825,"{'design_method': 'evo2_prompt_guided_v1', 'safety_method': 'heuristic_v1', 'safety_status': 'ok'}",local_invasion,TWIST1,p.Arg154Gln,Pathogenic,"Tier 2 - EMT regulator, metastasis promoter",63.82,0.36,0.499,PASS
TAATATTTGTCCCATTTACT,NGG,0.25,0.5,0.6,0.44825,"{'design_method': 'evo2_prompt_guided_v1', 'safety_method': 'heuristic_v1', 'safety_status': 'ok'}",local_invasion,TWIST1,p.Arg154Gln,Pathogenic,"Tier 2 - EMT regulator, metastasis promoter",,,,
AAATTAATCTATTAGCTAAT,NGG,0.15,0.4,0.6,0.40825,"{'design_method': 'evo2_prompt_guided_v1', 'safety_method': 'heuristic_v1', 'safety_status': 'ok'}",local_invasion,TWIST1,p.Arg154Gln,Pathogenic,"Tier 2 - EMT regulator, metastasis promoter",,,,
ATCCCAGCACTTTGGGAGGC,NGG,0.6,0.65,1.0,0.6282500000000001,"{'design_method': 'evo2_prompt_guided_v1', 'safety_method': 'heuristic_v1', 'safety_status': 'ok'}",intravasation,MMP2,p.Pro268Leu,Likely Pathogenic,Tier 2 - Matrix metalloproteinase,62.49,0.33,0.477,PASS
CCAGCACTTTGGGAGGCCAA,NGG,0.6,0.65,1.0,0.6282500000000001,"{'design_method': 'evo2_prompt_guided_v1', 'safety_method': 'heuristic_v1', 'safety_status': 'ok'}",intravasation,MMP2,p.Pro268Leu,Likely Pathogenic,Tier 2 - Matrix metalloproteinase,,,,
GCACTTTGGGAGGCCAAGGT,NGG,0.6,0.65,1.0,0.6282500000000001,"{'design_method': 'evo2_prompt_guided_v1', 'safety_method': 'heuristic_v1', 'safety_status': 'ok'}",intravasation,MMP2,p.Pro268Leu,Likely Pathogenic,Tier 2 - Matrix metalloproteinase,,,,
CGGAGAGCGGCGGGCGGGAG,NGG,0.85,0.4,0.6,0.40825,"{'design_method': 'evo2_prompt_guided_v1', 'safety_method': 'heuristic_v1', 'safety_status': 'ok'}",survival_in_circulation,BCL2,p.Gly101Asp,Pathogenic,"Tier 1 - Anti-apoptotic, venetoclax target",63.84,0.35,0.494,PASS
GAGAGCGGCGGGCGGGAGCG,NGG,0.85,0.4,0.6,0.40825,"{'design_method': 'evo2_prompt_guided_v1', 'safety_method': 'heuristic_v1', 'safety_status': 'ok'}",survival_in_circulation,BCL2,p.Gly101Asp,Pathogenic,"Tier 1 - Anti-apoptotic, venetoclax target",,,,
GCGGCGGGCGGGAGCGCGGC,NGG,0.95,0.3,0.6,0.36825,"{'design_method': 'evo2_prompt_guided_v1', 'safety_method': 'heuristic_v1', 'safety_status': 'ok'}",survival_in_circulation,BCL2,p.Gly101Asp,Pathogenic,"Tier 1 - Anti-apoptotic, venetoclax target",,,,
AGTTCACTGCAATCTCTGCC,NGG,0.5,0.75,1.0,0.668355,"{'design_method': 'evo2_prompt_guided_v1', 'safety_method': 'heuristic_v1', 'safety_status': 'ok'}",extravasation,ICAM1,p.Arg241Cys,Pathogenic,Tier 2 - Cell adhesion molecule,65.52,0.34,0.498,PASS
CTGTCACTCAGTCTAGAGTA,NGG,0.45,0.7,1.0,0.648355,"{'design_method': 'evo2_prompt_guided_v1', 'safety_method': 'heuristic_v1', 'safety_status': 'ok'}",extravasation,ICAM1,p.Arg241Cys,Pathogenic,Tier 2 - Cell adhesion molecule,,,,
TTTCATTTCCTCACTCTCCC,NGG,0.45,0.7,1.0,0.64825,"{'design_method': 'evo2_prompt_guided_v1', 'safety_method': 'heuristic_v1', 'safety_status': 'ok'}",micrometastasis_formation,CXCR4,p.Ser338Gly,Pathogenic,"Tier 2 - Chemokine receptor, homing signal",68.97,0.38,0.535,PASS
CAAGTTTCATTTCCTCACTC,NGG,0.4,0.65,1.0,0.6282500000000001,"{'design_method': 'evo2_prompt_guided_v1', 'safety_method': 'heuristic_v1', 'safety_status': 'ok'}",micrometastasis_formation,CXCR4,p.Ser338Gly,Pathogenic,"Tier 2 - Chemokine receptor, homing signal",,,,
CCCCGCCACTGATCCAGTTA,NGG,0.6,0.55,0.8,0.52825,"{'design_method': 'evo2_prompt_guided_v1', 'safety_method': 'heuristic_v1', 'safety_status': 'ok'}",micrometastasis_formation,CXCR4,p.Ser338Gly,Pathogenic,"Tier 2 - Chemokine receptor, homing signal",,,,
AGCCTCTTTCCTGCTAGAGC,NGG,0.55,0.7,1.0,0.64825,"{'design_method': 'evo2_prompt_guided_v1', 'safety_method': 'heuristic_v1', 'safety_status': 'ok'}",angiogenesis,VEGFA,p.Gly88Asp,Pathogenic,Tier 1 - FDA approved anti-VEGF drugs,66.73,0.38,0.524,PASS
CCATCCCTGCTCTGCAGAAC,NGG,0.6,0.65,1.0,0.6282500000000001,"{'design_method': 'evo2_prompt_guided_v1', 'safety_method': 'heuristic_v1', 'safety_status': 'ok'}",angiogenesis,VEGFA,p.Gly88Asp,Pathogenic,Tier 1 - FDA approved anti-VEGF drugs,,,,
CTGCAGAACCCCTGGGTGCT,NGG,0.65,0.5,0.6400000000000001,0.46025,"{'design_method': 'evo2_prompt_guided_v1', 'safety_method': 'heuristic_v1', 'safety_status': 'ok'}",angiogenesis,VEGFA,p.Gly88Asp,Pathogenic,Tier 1 - FDA approved anti-VEGF drugs,,,,
CAATGCTTTCCTATCTATAG,NGG,0.35,0.6,0.8,0.54825,"{'design_method': 'evo2_prompt_guided_v1', 'safety_method': 'heuristic_v1', 'safety_status': 'ok'}",metastatic_colonization,MET,p.Asp1010Asn,Pathogenic,Tier 1 - FDA approved MET inhibitors,65.45,0.36,0.507,PASS
